Cardiol Therapeutics(CRDL) - 2022 Q4 - Annual Report

Initiated patient enrollment in a Phase II open-label clinical trial investigating the safety, tolerability, and ef icacy of CardiolRx™ in patients with recurrent pericarditis - a debilitating heart disease associated with chest pain, shortness of breath and fatigue, resulting in markedly reduced quality of life, emergency department visits, and hospitalizations 2265 Upper Middle Road East, Suite 602 Oakville, ON L6H 0G5, Canada Cardiol Therapeutics Announces Year-End 2022 Update on Operations . Initiated p ...